亚宝药业：GLX002获得药物临床试验批准通知书

Core Viewpoint - The announcement indicates that the company's subsidiary, Yabao Biotech, has received approval from the National Medical Products Administration for the clinical trial of GLX002, a modified new drug based on bosentan dispersible tablets, aimed at treating pulmonary arterial hypertension (PAH) [1] Group 1: Product Details - GLX002 is designed for patients aged 1 year and older with idiopathic or congenital PAH, targeting improvements in pulmonary vascular resistance (PVR) [1] - The drug is intended to enhance exercise capacity in adult patients with WHO functional class II-IV PAH [1] Group 2: Regulatory Approval - The approval from the National Medical Products Administration is a significant milestone for the company, allowing it to proceed with clinical trials for GLX002 [1]